

Handbook of Pharmaceutical Excipients

Handbook of Pharmaceutical Excipients

FIFTH EDITION

Edited by

Raymond C Rowe

BPharm, PhD, DSc, FRPharmS, CChem,
FRSC, CPhys, MInstP

Chief Scientist

Intelligensys Ltd
Billingham, UK

Paul J Sheskey

BSc, RPh

Technical Services Leader

The Dow Chemical Company
Midland
MI, USA

Siân C Owen

BSc, MA

Development Editor

Royal Pharmaceutical Society of Great Britain
London, UK



London • Chicago

Published by the Pharmaceutical Press

Publications division of the Royal Pharmaceutical Society of Great Britain

1 Lambeth High Street, London SE1 7JN, UK
100 South Atkinson Road, Suite 206, Grayslake, IL 60030-7820, USA

and the American Pharmacists Association

2215 Constitution Avenue, NW, Washington, DC 20037-2985, USA

© Pharmaceutical Press and American Pharmacists Association 2006

 is a trademark of Pharmaceutical Press

First published 1986
Second edition published 1994
Third edition published 2000
Fourth edition published 2003
Fifth edition published 2006

Printed in Great Britain by Butler & Tanner, Frome, Somerset
Typeset by Data Standards Ltd, Frome, Somerset

ISBN 0 85369 618 7 (UK)
ISBN 1 58212 058 7 (USA)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder.

The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made.

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

Handbook of pharmaceutical excipients.—5th ed. / edited by Raymond C. Rowe, Paul J. Sheskey, Siân C. Owen.

p. ; cm.

Includes bibliographical references and index.

ISBN 1-58212-058-7 (USA) – ISBN 0-85369-618-7 (UK)

1. Excipients—Handbooks, manuals, etc.

[DNLM: 1. Excipients—Handbooks. 2. Technology, Pharmaceutical—Handbooks. QV 735 H236 2006] I. Rowe, Raymond C. II. Sheskey, Paul J. III. Owen, Siân C. IV. American Pharmacists Association.

RS201.E87H36 2006
615'.19—dc22

2005028523

Sucralose

1 Nonproprietary Names

USPNF: Sucralose

2 Synonyms

Splenda; TGS; 1',4',6'-trichlorogalactosucrose; 4,1',6'-trichloro-4,1',6'-trideoxy-galacto-sucrose.


3 Chemical Name and CAS Registry Number

1,6-Dichloro-1,6-dideoxy- β -D-fructofuranosyl-4-chloro-4-deoxy- α -D-galactopyranoside [56038-13-2]

4 Empirical Formula and Molecular Weight

C₁₂H₁₉Cl₃O₈ 397.64

5 Structural Formula



6 Functional Category

Sweetening agent.

7 Applications in Pharmaceutical Formulation or Technology

Sucralose is used as a sweetening agent in beverages, foods, and pharmaceutical applications. It has a sweetening power approximately 300–1000 times that of sucrose and has no aftertaste. It has no nutritional value, is noncariogenic, and produces no glycemic response. *See also* Table I.

Table I: Uses of sucralose.

Use	Concentration (%)
Food products	0.03–0.24

8 Description

Sucralose is a white to off-white colored, free-flowing, crystalline powder.

9 Pharmacopeial Specifications

See Table II.

Table II: Pharmacopeial specifications for sucralose.

Test	USPNF 23
Identification	+
Specific rotation	+84.0° to +87.5°
Water	≤2.0%
Residue on ignition	≤0.7%
Heavy metals	≤0.001%
Limit of hydrolysis products	≤0.1%
Limit of methanol	≤0.1%
Related compounds	≤0.5%
Assay (dried basis)	98.0–102.0%

10 Typical Properties

Acidity/alkalinity: pH = 5–6 (10% w/v aqueous solution at 20°C)

Density (bulk): 0.35 g/cm³

Density (tapped): 0.62 g/cm³

Density (true): 1.63 g/cm³

Melting point: 130°C (for anhydrous crystalline form); 36.5°C (for pentahydrate).

Particle size distribution: 90% < 12 μm in size.

Partition coefficient: log₁₀ P = –0.51 (octanol:water)

Refractive index: 1.33 to 1.37

Solubility: freely soluble in ethanol (95%), methanol, and water; slightly soluble in ethyl acetate.

Specific rotation [α]_D²⁰: +84.0° to +87.5° (1% w/v aqueous solution); +68.2° (1.1% w/v solution in ethanol).

Viscosity: 0.6–3.8 mPa s

11 Stability and Storage Conditions

Sucralose is a relatively stable material. In aqueous solution, at highly acidic conditions (pH < 3), and at high temperatures (≤35°C), it is hydrolyzed to a limited extent, producing 4-chloro-4-deoxygalactose and 1,6-dichloro-1,6-dideoxyfructose. In food products, sucralose remains stable throughout extended storage periods, even at low pH. However, it is most stable at pH 5–6.

Sucralose should be stored in a well-closed container in a cool, dry place, at a temperature not exceeding 21°C. Sucralose, when heated at elevated temperatures, may break down with the release of carbon dioxide, carbon monoxide, and minor amounts of hydrogen chloride.

12 Incompatibilities

13 Method of Manufacture

Sucralose may be prepared by a variety of methods that involve the selective substitution of three sucrose hydroxyl groups by chlorine. Sucralose can also be synthesized by the reaction of sucrose (or an acetate) with thionyl chloride.

14 Safety

Sucralose is generally regarded as a nontoxic and nonirritant material and is approved, in a number of countries, for use in food products. Following oral consumption, sucralose is mainly unabsorbed and is excreted in the feces.^(1–3)

The WHO has set an acceptable daily intake for sucralose of up to 15 mg/kg body-weight.⁽⁴⁾

LD₅₀ (mouse, oral): > 16 g/kg

LD₅₀ (rat, oral): > 10 g/kg

15 Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled.

16 Regulatory Status

The FDA, in April 1998, approved sucralose for use as a tabletop sweetener and as an additive in a variety of food products. In the UK, sucralose was authorized for use in food products on a 2-year temporary basis in March 2002.⁽⁵⁾ It is also accepted for use in many other countries worldwide. Included in the Canadian List of Acceptable Non-medicinal Ingredients.

17 Related Substances

Sucrose.

18 Comments

The sweetening effect of sucralose is not reduced by heating and food products containing sucralose may be subjected to high-temperature processes such as pasteurization, sterilization, UHT processing and baking. Sucralose is often blended with maltodextrin or dextrose as bulking agents in its granular form.

A specification for sucralose is contained in the Food Chemicals Codex (FCC).

19 Specific References

- 1 Grice HC, Goldsmith LA. Sucralose – an overview of the toxicity data. *Food Chem Toxicol* 2000; 38 (Suppl. 2): S1–S6.
- 2 Roberts A, Renwick AG, Sims J, Snodin DJ. Sucralose metabolism and pharmacokinetics in man. *Food Chem Toxicol* 2000; 38 (Suppl. 2): S31–S41.
- 3 Mclean Baird I, Shephard NW, Merritt RJ, Hildick-Smith G. Repeated dose study of sucralose tolerance in human subjects. *Food Chem Toxicol* 2000; 38(Suppl 2): S123–S129.
- 4 FAO/WHO. Evaluation of certain food additives and contaminants. Thirty-seventh report of the joint FAO/WHO expert committee on food additives. *World Health Organ Tech Rep Ser* 1991; No. 806: 21–23.
- 5 Statutory Instrument (SI) 2002: No. 379. The Sweeteners in Food (Amendment) (England) Regulations 2002. London: Stationery Office, 2002.

20 General References

- American Dietetic Association. Position of the American Dietetic Association: use of nutritive and nonnutritive sweeteners. *J Am Diet Assoc* 2004; 104: 255–275.
- Anonymous. Artificial sweeteners. *Can Pharm J* 1996; 129(Apr): 22.
- Anonymous. Sucralose – a new artificial sweetener. *Med Lett Drugs Ther* 1998; 40: 67–68.
- Jenner MR, Smithson A. Physicochemical properties of the sweetener sucralose. *J Food Sci* 1989; 54(6): 1646–1649.
- Kloesel L. Sugar substitutes. *Int J Pharm Compound* 2000; 4(2): 86–87.
- Knight I. The development and applications of sucralose, a new high-intensity sweetener. *Can J Physiol Pharmacol* 1994; 72(4): 435–439.
- Kroschwitz JI, Howe-Grant M, eds. In: *Kirk-Othmer Encyclopedia of Chemical Technology*, 4th edn. New York: John Wiley & Sons, 1994; 11: 295.
- McNeil Nutritionals. Splenda: the online guide to cooking, eating and living well. <http://www.splenda.com> (accessed 31 February 2004).
- Tate and Lyle. Technical literature: *Sucralose*. 2001.

21 Authors

BA Langdon, MP Mullarney.

22 Date of Revision

26 August 2005.

Sucrose

1 Nonproprietary Names

BP: Sucrose
JP: Sucrose
PhEur: Saccharum
USPNF: Sucrose

2 Synonyms

Beet sugar; cane sugar; α -D-glucopyranosyl- β -D-fructofuranoside; refined sugar; saccharose; sugar.


3 Chemical Name and CAS Registry Number

β -D-fructofuranosyl- α -D-glucopyranoside [57-50-1]

4 Empirical Formula and Molecular Weight

$C_{12}H_{22}O_{11}$ 342.30

5 Structural Formula



6 Functional Category

Base for medicated confectionery; coating agent; granulating agent; sugar coating adjunct; suspending agent; sweetening agent; tablet binder; tablet and capsule diluent; tablet filler; viscosity-increasing agent.

7 Applications in Pharmaceutical Formulation or Technology

Sucrose is widely used in oral pharmaceutical formulations.

Sucrose syrup, containing 50–67% w/w sucrose, is used in tableting as a binding agent for wet granulation. In the powdered form, sucrose serves as a dry binder (2–20% w/w) or as a bulking agent and sweetener in chewable tablets and lozenges.^(1,2) Tablets that contain large amounts of sucrose may harden to give poor disintegration.

Sucrose syrups are used as tablet-coating agents at concentrations between 50% and 67% w/w. With higher concentrations, partial inversion of sucrose occurs, which makes sugar coating difficult.

Sucrose syrups are also widely used as vehicles in oral liquid-dosage forms to enhance palatability or to increase viscosity.^(3,4)

Sucrose has been used as a diluent in freeze-dried protein products.^(5,6)

Sucrose is also widely used in foods and confectionery, and therapeutically in sugar pastes that are used to promote wound healing.^(7,8) See Table I.

Table I: Uses of sucrose.

Use	Concentration (% w/w)
Syrup for oral liquid formulations	67
Sweetening agent	67
Tablet binder (dry granulation)	2–20
Tablet binder (wet granulation)	50–67
Tablet coating (syrup)	50–67

8 Description

Sucrose is a sugar obtained from sugar cane (*Saccharum officinarum* Linné (Fam. Gramineae)), sugar beet (*Beta vulgaris* Linné (Fam. Chenopodiaceae)), and other sources. It contains no added substances. Sucrose occurs as colorless crystals, as crystalline masses or blocks, or as a white crystalline powder; it is odorless and has a sweet taste.

9 Pharmacopeial Specifications

See Table II.

10 Typical Properties

Density (bulk):

0.93 g/cm³ (crystalline sucrose);

0.60 g/cm³ (powdered sucrose).

Density (tapped):

1.03 g/cm³ (crystalline sucrose);

0.82 g/cm³ (powdered sucrose).

Density (true): 1.6 g/cm³

Dissociation constant: $pK_a = 12.62$

Flowability: crystalline sucrose is free flowing, whereas powdered sucrose is a cohesive solid.

Melting point: 160–186°C (with decomposition)

Moisture content: finely divided sucrose is hygroscopic and absorbs up to 1% water.⁽⁹⁾ See Figure 1.

Osmolarity: a 9.25% w/v aqueous solution is isoosmotic with serum.

Particle size distribution: powdered sucrose is a white, irregular-sized granular powder. The crystalline material consists of colorless crystalline, roughly cubic granules. See Figures 2 and 3.

Table II: Pharmacopeial specifications for sucrose.

Test	JP 2001	PhEur 2005	USPNF 23
Identification	+	+	+
Characters	—	+	—
Appearance of solution	+	+	—
Acidity or alkalinity	+	+	—
Specific optical rotation	+66.3° to +67.0°	+66.3° to +67.0°	≥ +65.9°
Color value	—	≤ 45	—
Conductivity	+	+	—
Loss on drying	≤ 0.1%	≤ 0.1%	—
Bacterial endotoxins ^(a)	≤ 0.25 IU/mg	≤ 0.25 IU/mg	—
Dextrins ^(a)	+	+	—
Reducing sugars	—	+	—
Invert sugar	+	—	+
Chloride	—	—	≤ 0.0035%
Sulfate	—	—	≤ 0.006%
Sulfites	≤ 15 ppm	≤ 10 ppm	—
Calcium	—	—	≤ 5 ppm
Heavy metals	—	—	≤ 5 ppm
Lead	≤ 0.5 ppm	≤ 0.5 ppm	—
Residue on ignition	—	—	≤ 0.05%
Organic volatile impurities	—	—	+

^(a) If sucrose is to be used in large volume infusions.

Refractive index: $n_D^{25} = 1.34783$ (10% w/v aqueous solution)

Solubility: see Table III.

Specific gravity: see Table IV.

Table III: Solubility of sucrose.

Solvent	Solubility at 20°C unless otherwise stated
Chloroform	Practically insoluble
Ethanol	1 in 400
Ethanol (95%)	1 in 170
Propan-2-ol	1 in 400
Water	1 in 0.5
	1 in 0.2 at 100°C

Table IV: Specific gravity of aqueous sucrose solutions.

Concentration of aqueous sucrose solution (% w/w)	Specific gravity at 20°C
2	1.0060
6	1.0219
10	1.0381
20	1.0810
30	1.1270
40	1.1764
50	1.2296
60	1.2865
70	1.3471
76	1.3854

SEM: 1


Excipient: Sucrose

Manufacturer: Great Western Sugar Co.

Lot No.: 1-2-80

Magnification: 60×

Voltage: 10 kV



SEM: 2


Excipient: Sucrose

Manufacturer: Great Western Sugar Co.

Lot No.: 1-2-80

Magnification: 600×

Voltage: 10 kV



11 Stability and Storage Conditions

Sucrose has good stability at room temperature and at moderate relative humidity. It absorbs up to 1% moisture, which is released upon heating at 90°C. Sucrose caramelizes when heated to temperatures above 160°C. Dilute sucrose solutions are liable to fermentation by microorganisms but resist decomposition at higher concentrations, e.g., above 60%

w/w concentration. Aqueous solutions may be sterilized by autoclaving or filtration.

When sucrose is used as a base for medicated confectionery, the cooking process, at temperatures rising from 110 to 145°C, causes some inversion to form dextrose and fructose (invert sugar). The fructose imparts stickiness to confectionery but prevents cloudiness due to graining. Inversion is accelerated particularly at temperatures above 130°C and by the presence of acids.

The bulk material should be stored in a well-closed container in a cool, dry place.




Figure 1: Moisture sorption-desorption isotherm of powdered sucrose. Samples dried initially at 60°C over silica gel for 24 hours. Note: at 90% relative humidity, sufficient water was absorbed to cause dissolution of the solid.

12 Incompatibilities

Powdered sucrose may be contaminated with traces of heavy metals, which can lead to incompatibility with active ingredients, e.g. ascorbic acid. Sucrose may also be contaminated with sulfite from the refining process. With high sulfite content, color changes can occur in sugar-coated tablets; for certain colors used in sugar-coating the maximum limit for sulfite content, calculated as sulfur, is 1 ppm. In the presence of dilute or concentrated acids, sucrose is hydrolyzed or inverted to dextrose and fructose (invert sugar). Sucrose may attack aluminum closures.⁽¹⁰⁾

13 Method of Manufacture

Sucrose is obtained from the sugar cane plant, which contains 15–20% sucrose, and sugar beet, which contains 10–17% sucrose. Juice from these sources is heated to coagulate water-soluble proteins, which are removed by skimming. The resultant solution is then decolorized with an ion-exchange resin or charcoal and concentrated. Upon cooling, sucrose crystallizes out. The remaining solution is concentrated again and yields more sucrose, brown sugar, and molasses.




Figure 2: Particle size distribution of crystalline sucrose.




Figure 3: Particle size distribution of powdered sucrose.

14 Safety

Sucrose is hydrolyzed in the small intestine by the enzyme sucrase to yield dextrose and fructose, which are then absorbed. When administered intravenously, sucrose is excreted unchanged in the urine.

Although sucrose is very widely used in foods and pharmaceutical formulations, sucrose consumption is a cause of concern and should be monitored in patients with diabetes mellitus or other metabolic sugar intolerance.⁽¹¹⁾

Sucrose is also considered to be more cariogenic than other carbohydrates since it is more easily converted to dental plaque.

For this reason, its use in oral pharmaceutical formulations is declining.

Although sucrose has been associated with obesity, renal damage, and a number of other diseases, conclusive evidence linking sucrose intake with some diseases could not be established.^(12,13) It was, however, recommended that sucrose intake in the diet should be reduced.⁽¹³⁾

LD₅₀ (mouse, IP): 14 g/kg⁽¹⁴⁾

LD₅₀ (rat, oral): 29.7 g/kg

15 Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye protection and gloves are recommended. In the UK, the occupational exposure limit for sucrose is 10 mg/m³ long-term (8-hour TWA) and 20 mg/m³ short-term.⁽¹⁵⁾

16 Regulatory Status

GRAS listed. Included in the FDA Inactive Ingredients Guide (injections; oral capsules, solutions, syrups, and tablets; topical preparations). Included in nonparenteral and parenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.

17 Related Substances

Compressible sugar; confectioner's sugar; invert sugar; sugar spheres.

Invert sugar

Empirical formula: C₆H₁₂O₆

Molecular weight: 180.16

CAS number: [8013-17-0]

Comments: an equimolecular mixture of dextrose and fructose prepared by the hydrolysis of sucrose with a suitable mineral acid such as hydrochloric acid. Invert sugar may be used as a stabilizing agent to help prevent crystallization of sucrose syrups and graining in confectionery. A 10% aqueous solution is also used in parenteral nutrition.

18 Comments

For typical boiling points of sucrose syrups, without inversion of the sugar, see Table V. A specification for sucrose is contained in the Food Chemicals Codex (FCC).

The EINECS number for sucrose is 200-334-9.

Table V: Boiling points of sucrose syrups.

Sucrose concentration (% w/v)	Boiling point (°C)
50	101.5
60	103
64	104
72	105.5
75	107
77.5	108.5
80	110.5

19 Specific References

- Allen LV. Featured excipient: capsule and tablet diluents. *Int J Pharm Compound* 2000; 4(4): 306–310, 324–325.
- Mullarney MP, Hancock BC, Carlson GT, *et al.* The powder flow and compact mechanical properties of sucrose and three high intensity sweeteners used in chewable tablets. *Int J Pharm* 2003; 257(1–2): 227–236.
- Salazar DSM, Saavedra C. Application of a sensorial response model to the design of an oral liquid pharmaceutical dosage form. *Drug Dev Ind Pharm* 2000; 26(1): 55–60.
- Cooper J. A question of taste: uses of sucrose. *Manuf Chem* 2003; 74(10): 71–72, 74.
- Izutsu K, Kojima S. Excipient crystallinity and its protein structure stabilizing effect during freeze-drying. *J Pharm Pharmacol* 2002; 54(8): 1033–1039.
- Johnson RE, Kirchoff CF, Gand HE. Mannitol-sucrose mixtures: versatile formulations for protein lyophilisation. *J Pharm Sci* 2002; 91(4): 914–922.
- Middleton KR, Seal D. Sugar as an aid to wound healing. *Pharm J* 1985; 235: 757–758.
- Thomas S. *Wound Management and Dressings*. London: Pharmaceutical Press, 1990: 62–63.
- Hancock BC, Dalton CR. Effect of temperature on water vapour sorption by some amorphous pharmaceutical sugars. *Pharm Dev Technol* 1999; 4(1): 125–131.
- Tressler LJ. Medicine bottle caps [letter]. *Pharm J* 1985; 235: 99.
- Golightly LK, Smolinske SS, Bennett ML, *et al.* Pharmaceutical excipients: adverse effects associated with 'inactive' ingredients in drug products (part II). *Med Toxicol* 1988; 3: 209–240.
- Yudkin J. Sugar and disease. *Nature* 1972; 239: 197–199.
- Anonymous. *Report on Health and Social Subjects* 37. London: HMSO, 1989.
- Lewis RJ, ed. *Sax's Dangerous Properties of Industrial Materials*, 11th edn. New York: Wiley, 2004: 3318.
- Health and Safety Executive. *EH40/2002: Occupational Exposure Limits 2002*. Sudbury: Health and Safety Executive, 2002.

20 General References

- Armstrong NA. In: Swarbrick J, Boylan JC, eds. *Encyclopedia of Pharmaceutical Technology*, 2nd edn, vol. 3. New York: Marcel Dekker, 2002: 2713–2732.
- Barry RH, Weiss M, Johnson JB, DeRitter E. Stability of phenylpropanolamine hydrochloride in liquid formulations containing sugars. *J Pharm Sci* 1982; 71: 116–118.
- Jackson EB, ed. *Sugar Confectionery Manufacture*. Glasgow: Blackie, 1990.
- Lipari JM, Reiland TL. Flavors and flavor modifiers. In: Swarbrick J, Boylan JC, eds. *Encyclopedia of Pharmaceutical Technology*, 2nd edn, vol. 2. New York: Marcel Dekker, 2002: 1255–1263.
- Wolraich ML, Lindgreen SD, Stumbo PJ, *et al.* Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. *N Engl J Med* 1994; 330: 301–307.

21 Authors

NA Armstrong.

22 Date of Revision

17 August 2005.

Sugar, Compressible

1 Nonproprietary Names

USPNF: Compressible sugar

2 Synonyms

Di-Pac; direct compacting sucrose.

3 Chemical name and CAS Registry Number

See Sections 4 and 18.

4 Empirical Formula and Molecular Weight

The USPNF 23 states that compressible sugar contains not less than 95.0% and not more than 98.0% of sucrose ($C_{12}H_{22}O_{11}$). It may contain starch, maltodextrin, or invert sugar, and may contain a suitable lubricant.

5 Structural Formula

See Section 4.

6 Functional Category

Sweetening agent; tablet and capsule diluent.

7 Applications in Pharmaceutical Formulation or Technology

Compressible sugar is used primarily in the preparation of direct-compression chewable tablets. Its tableting properties can be influenced by small changes in moisture level;^(1,2) see Table I.

Table I: Uses of compressible sugar.

Use	Concentration (%)
Dry binder in tablet formulations	5–20
Filler in chewable tablets	20–60
Filler in tablets	20–60
Sweetener in chewable tablets	10–50

8 Description

Compressible sugar is a sweet-tasting, white, crystalline powder.

9 Pharmacopeial Specifications

See Table II.

Table II: Pharmacopeial specifications for compressible sugar.

Test	USPNF 23
Identification	+
Calcium	+
Chloride	≤0.014%
Heavy metals	≤5 ppm
Loss on drying	0.25–1.0%
Residue on ignition	≤0.1%
Microbial limits	+
Organic volatile impurities	+
Sulfate	≤0.010%
Assay	95.0–98.0%

10 Typical Properties

Density (bulk): 0.492 g/cm³

Density (tapped): 0.6 g/cm³

Moisture content: 0.57%

Particle size distribution: for *Di-Pac*, 3% maximum retained on a #40 (425 μm) mesh; 75% minimum through a #100 (150 μm) mesh; 5% maximum through #200 (75 μm) mesh.

Solubility: the sucrose portion is water-soluble.

Specific surface area: 0.13–0.14 m²/g

11 Stability and Storage Conditions

Compressible sugar is stable in air under normal storage conditions of room temperature and low relative humidity. The bulk material should be stored in a well-closed container in a cool, dry place.

12 Incompatibilities

Incompatible with dilute acids, which cause hydrolysis of sucrose to invert sugar, and with alkaline earth hydroxides, which react with sucrose to form sucrates.

13 Method of Manufacture

Compressible sugar is prepared by cocrystallization of sucrose with other excipients such as maltodextrin.⁽¹⁾ Compressible sugar may also be prepared using a dry granulation process.

14 Safety

Compressible sugar is generally regarded as a relatively nontoxic and nonirritant material. See also Sucrose.

15 Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. See also Sucrose.

16 Regulatory Status

Included in the FDA Inactive Ingredients Guide (oral capsules and tablets). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.

17 Related Substances

Confectioner's sugar; sucrose; sugar spheres; *Sugartab*.

Sugartab

Appearance: *Sugartab* (JRS Pharma LC) is a compressible sugar that does not conform to the USPNF 23 specification. It is an agglomerated sugar product containing approximately 90–93% sucrose, the balance being invert sugar.

Density (bulk): 0.60 g/cm³

Density (tapped): 0.69 g/cm³

EINECS number: [64333-34-2]

Flowability: 42.7 g/s

Moisture content: 0.20–0.57%.

Particle size distribution: 30% through a #20 (850 µm) mesh; 3% through a #30 (600 µm) mesh.

18 Comments

—

19 Specific References

- 1 Rizzuto AB, Chen AC, Veiga MF. Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. *Pharm Technol* 1984; 8(9): 32, 34, 36, 38–39.
- 2 Tabibi SE, Hollenbeck RG. Interaction of water vapor and compressible sugar. *Int J Pharm* 1984; 18: 169–183.

20 General References

- JRS Pharma LC. Technical literature: *Sugartab*, 2003.
- Mendes RW, Gupta MR, Katz IA, O'Neil JA. Nu-tab as a chewable direct compression carrier. *Drug Cosmet Ind* 1974; 115(6): 42–46, 130–133.
- Ondari CO, Kean CE, Rhodes CT. Comparative evaluation of several direct compression sugars. *Drug Dev Ind Pharm* 1983; 9: 1555–1572.
- Ondari CO, Kean CE, Rhodes CT. Comparative evaluation of several direct compression sugars. *Drug Dev Ind Pharm* 1988; 14: 1517–1527.
- Shangraw RF, Wallace JW, Bowers FM. Morphology and functionality in tablet excipients for direct compression. *Pharm Technol* 1981; 5: 69–78.

21 Authors

AW Wood.

22 Date of Revision

17 August 2005.